Rashi Peripherals Appoints Rajesh Goenka as CEO and Dr. Indumati Gopinathan as Independent Director

1 min read     Updated on 03 Feb 2026, 08:57 PM
scanx
Reviewed by
Jubin VScanX News Team
Overview

Rashi Peripherals Limited appointed two additional directors on February 3, 2026, with Rajesh Goenka taking on the role of Whole-Time Director and CEO for a five-year term, and Dr. Indumati Gopinathan joining as Independent Director until the 38th AGM. Goenka brings over 25 years of sales and marketing experience and has been with the company since 2008, while Dr. Gopinathan contributes healthcare expertise as a pathologist and current Independent Director at Thyrocare Technologies Limited.

31678058

*this image is generated using AI for illustrative purposes only.

Rashi Peripherals Limited announced significant board changes on February 3, 2026, with the appointment of two additional directors following recommendations from the Nomination and Remuneration Committee. The appointments were made in compliance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Key Board Appointments

The board approved two strategic appointments that will strengthen the company's leadership structure:

Position Name Term Effective Date
Whole-Time Director & CEO Mr. Rajesh Goenka (DIN: 10985108) 5 years February 3, 2026 to February 2, 2031
Independent Director Dr. Indumati Gopinathan (DIN: 06779331) Until 38th AGM February 3, 2026

Rajesh Goenka's Leadership Profile

Mr. Rajesh Goenka brings substantial experience to his new role as Chief Executive Officer. He holds a Bachelor's degree in Chemical Engineering from Pune University and has accumulated over 25 years of extensive experience in sales and marketing. His association with the company dates back to 2008, where he has played a pivotal role in driving growth through strategic vision and leadership.

Goenka has been instrumental in shaping the company's remarkable journey, leading it to achieve consistent double-digit compound annual growth rate (CAGR) for over 20 years. His appointment as Whole-Time Director and CEO reflects the board's confidence in his ability to continue steering the company's growth trajectory.

Dr. Indumati Gopinathan's Expertise

Dr. Indumati Gopinathan joins as an Additional Non-Executive Independent Director, bringing diverse professional experience from the healthcare sector. She is an experienced pathologist with MBBS and MD degrees from Seth G.S. Medical College, Mumbai, and has led pathology departments in leading hospitals with specialization in ocular pathology and uropathology.

Her professional portfolio includes:

  • Current role as Independent Director at Thyrocare Technologies Limited
  • Leadership positions in National AIDS Control Organization and Indian Medical Association
  • Pioneer in telemedicine initiatives
  • Completion of Masterclass on Women Directorship by NSE Limited
  • Active involvement in healthcare governance and social impact projects

Regulatory Compliance and Next Steps

Both appointments comply with SEBI regulations and require approval from the company's members. The directors have confirmed that neither appointee is debarred from holding directorial positions by SEBI or any other regulatory authority. The appointments reflect Rashi Peripherals' commitment to strengthening its board composition with experienced professionals who can contribute to the company's strategic objectives and governance standards.

Historical Stock Returns for Rashi Peripherals

1 Day5 Days1 Month6 Months1 Year5 Years
+3.50%+8.02%+1.15%+26.13%+13.25%+13.51%

Rashi Peripherals Q3FY26 Results: Revenue Hits ₹40.30B, Appoints New CEO

1 min read     Updated on 29 Jan 2026, 12:59 PM
scanx
Reviewed by
Naman SScanX News Team
Overview

Rashi Peripherals delivered strong Q3FY26 results with consolidated revenue of ₹40.30 billion, up 42.61% year-on-year, and net profit of ₹745.94 million, representing 132.60% growth. The company made strategic leadership appointments including Mr. Rajesh Goenka as CEO and approved formation of a UAE subsidiary for ICT distribution.

31217361

*this image is generated using AI for illustrative purposes only.

Rashi Peripherals Limited has announced its consolidated financial results for Q3FY26 ended December 31, 2025, demonstrating strong performance across key metrics. The company also made significant leadership appointments and strategic expansion moves during the quarter.

Q3FY26 Financial Performance

The company delivered robust consolidated financial results for the quarter ended December 31, 2025:

Metric: Q3FY26 Q3FY25 YoY Growth
Consolidated Revenue: ₹40,304.12 million ₹28,263.07 million +42.61%
Consolidated Net Profit: ₹745.94 million ₹320.70 million +132.60%
Standalone Revenue: ₹38,044.96 million ₹26,511.45 million +43.49%
Standalone Net Profit: ₹702.80 million ₹308.28 million +128.02%

The consolidated revenue of ₹40,304.12 million represents a significant increase from ₹28,263.07 million in the corresponding quarter of the previous year. Net profit after tax surged to ₹745.94 million compared to ₹320.70 million in Q3FY25.

Leadership Appointments

The company announced two key leadership appointments effective February 3, 2026:

Position: Details
CEO & Whole-Time Director: Mr. Rajesh Goenka (DIN: 10985108)
Term: 5 years (February 3, 2026 to February 2, 2031)
Independent Director: Dr. Indumati Gopinathan (DIN: 06779331)
Tenure: Until 38th Annual General Meeting

Mr. Rajesh Goenka brings over 25 years of experience in sales and marketing, having been associated with the company since 2008. Dr. Indumati Gopinathan is an experienced pathologist with leadership roles in healthcare organizations.

Strategic Expansion and Corporate Actions

The company approved the formation of a step-down subsidiary in UAE, which will be wholly-owned by Rashi Peripherals Pte. Ltd. The new entity, Rashi Peripherals LLC, will have authorized capital of UAE Dirham 1,00,000 with investment up to US$ 5,00,000.

Development: Details
UAE Subsidiary: Rashi Peripherals LLC
Investment: Up to US$ 5,00,000
Business Focus: ICT Product Distribution
Internal Auditor: M/s. GMJ & Co. reappointed for FY2026-27

IPO Proceeds Utilization

As of December 31, 2025, the company has substantially utilized its IPO proceeds of ₹554.14 crore, with ₹552.53 crore deployed and only ₹1.61 crore remaining unutilized under General Corporate Purposes. The monitoring agency CARE Ratings Limited reported no deviations in fund utilization during the quarter.

Historical Stock Returns for Rashi Peripherals

1 Day5 Days1 Month6 Months1 Year5 Years
+3.50%+8.02%+1.15%+26.13%+13.25%+13.51%

More News on Rashi Peripherals

1 Year Returns:+13.25%